Lexaria Bioscience Corp (NASDAQ: LEXX) is a drug delivery technology company that develops and licenses its proprietary DehydraTECH platform, which is designed to improve oral bioavailability of lipophilic active pharmaceutical ingredients. Revenue is generated primarily through licensing agreements granted to third parties for use of DehydraTECH across pharmaceutical, nutraceutical, and consumer product applications. The company is pre-commercial in its pharmaceutical programs, with R&D activity centered on DehydraTECH-enhanced GLP-1 and GIP drugs, including semaglutide, liraglutide, and tirzepatide, as well as cannabidiol applications for hypertension and diabetes. As of the 10-K filed November 28, 2025, Lexaria held an extensive patent portfolio spanning the US, Australia, Europe, Japan, Canada, and Mexico, covering food, beverage, transdermal, and pharmaceutical delivery formats. The company is headquartered in British Columbia, Canada, and its common stock trades on Nasdaq under the symbol LEXX. Competitors include major multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, and academic research institutions.

Revenue model

Lexaria generates revenue through licensing its DehydraTECH drug delivery technology to third parties, including non-exclusive and exclusive licenses for specific geographies, active pharmaceutical ingredients, and product formats. Altria Ventures Inc. holds a 16.667% equity interest in subsidiary Lexaria Nicotine LLC, indicating a joint-venture structure for nicotine-related applications.

Products and services

DehydraTECH is the company's sole drug delivery platform, engineered to enhance oral absorption of lipophilic active agents. Applications under active R&D as of the 10-K filed November 28, 2025 include DehydraTECH-semaglutide, DehydraTECH-tirzepatide, DehydraTECH-liraglutide, and DehydraTECH-CBD, with indications targeting weight loss, diabetes, and hypertension. The patent portfolio covers food and beverage infusions, transdermal delivery, nicotine compositions, and pharmaceutical oral dosage forms across multiple patent families.

Customers and end markets

Licensees include AnodGen Bioceutical (Europe, Australia, New Zealand), Valcon Medical A/S (Europe), Lexaria (AU) Pty Ltd (Australia), Bevnology LLC (US non-pharmaceutical formats), and SulfoSyn Limited (worldwide). End markets span pharmaceutical drug delivery, nutraceuticals, functional beverages, nicotine products, and topical formulations.

Value-chain role

Lexaria operates as a drug delivery technology licensor, positioned upstream of product manufacturers and marketers. It does not manufacture end products. It conducts preclinical and clinical research internally and through contract research organizations, then licenses its technology for third parties to develop and commercialize finished products.

Geographic exposure

Lexaria is headquartered in British Columbia, Canada, and is a reporting issuer in both the US and Canada. Its patent coverage spans the US, Australia, Europe (including the UK), Japan, Canada, Mexico, and India. Licensing agreements cover territories including Europe, Australia, New Zealand, and the US.

Competitors

Major multinational pharmaceutical companies, Established biotechnology companies, Specialty pharmaceutical companies, Universities and academic research institutions

Source: SEC 10-K, filed 2025-11-28

Industry: Pharmaceutical Preparations Peers: Lucy Scientific Discovery, Inc.